DB01208ApprovedWithdrawnSmall molecule
Sparfloxacin is a fluoroquinolone antibiotic used to treat bacterial respiratory infections and sinusitis. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase.
- Mechanism
- Curator reviewed
The bactericidal action of sparfloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.
- Primary indication
- For the treatment of adults with the following infections caused by susceptible strains microorganisms: community-acquired pneumonia (caused by Chlamydia pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, or Streptococcus pneumoniae) and acute bacterial exacerbations...Curator reviewed · 4 structured indications
- Formula / weight
- C19H22F2N4O3 · 392.3998 g/mol (avg)
- Code names
- AT-4140 · CI-978
Resolves to
Clinical / RWD
Structure
InChIKey
DZZWHBIBMUVIIW-DTORHVGOSA-NSMILESC[C@H]1CN(C[C@@H](C)N1)C1=C(F)C(N)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=OWhat you can answer from here — as of September 23, 2026
8Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
5TransportersSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Sparfloxacin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account